How effective is surgical treatment for ductal carcinoma in situ (DCIS) at preventing an invasive recurrence of breast cancer? Treatment is intended to significantly lessen the lifetime risk of breast cancer and breast cancer-related mortality, but are patients diagnosed with DCIS still at risk for experiencing poor outcomes? A recent study in JAMA Network Open…
Two recent studies examined the benefits of using a 3D bioabsorbable marker to indicate the tumor bed in women with breast cancer who underwent breast conserving surgery (BCS).
Male breast cancer patients are less likely than their female counterparts to receive adjuvant hormone therapy and postlumpectomy radiation.
Cancers that cause more readily noticeable physical changes can produce self-image challenges for patients. This discussion reviews what interventions can help validate patients’ self-image concerns.
Better breast reconstruction outcomes may be one reason behind the trend of increasing mastectomy rates for early-stage breast cancer patients eligible for lumpectomy.
Frozen section analysis during breast cancer lumpectomies spared patients the need for a repeat lumpectomy in about 96% of cases, according to a new study.
When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments.
Women with stage I or II breast cancer who had breast-conserving therapy plus radiation survived longer than did women undergoing mastectomy.
MALND, en endoscopic technique to determine if breast cancer has spread to the adjoining lymph nodes, can reduce the complications associated with the conventional surgical approach to axillary lymph node dissection.
Most older women with early breast cancer are more likely to avoid mastectomy by following lumpectomy with radiation, contrary to current thinking.
